Form 4: REGENXBIO CEO Kenneth T. Mills Executes Stock Options and Sells Shares

REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold shares on March 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 14, 2024, Kenneth T. Mills, the President and CEO of REGENXBIO Inc., executed stock options to acquire 15,000 shares of common stock at a price of $3.76 per share.
• Simultaneously, Mills sold 15,000 shares of common stock at a weighted average price of $21.8628, with individual sales prices ranging from $21.60 to $22.31.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
• Following these transactions, Mills directly owns 408,035 shares of REGENXBIO common stock and holds options to purchase 111,354 shares.

Sentiment

Score: 5

Explanation: Neutral. This is a standard Form 4 filing reflecting pre-planned transactions under a 10b5-1 trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management. The use of a 10b5-1 plan suggests these transactions were pre-planned.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on current insider knowledge.

Key Dates